# C1-2026-02383: FDA Fixes Typo: Heart Device Patent Gets Two Extra Months

C1-2026-02383, Determination of Regulatory Review Period for Purposes of Patent Extension; AURORA EV-ICD, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-03-10 (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/C1-2026-02383
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: C1-2026-02383
- Title: Determination of Regulatory Review Period for Purposes of Patent Extension; AURORA EV-ICD
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 11557
- Published: 2026-03-10
- Effective: unknown
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Fixes Typo: Heart Device Patent Gets Two Extra Months

## Summary

The FDA fixed a date typo in their earlier announcement about the AURORA EV-ICD patent review period. This update changes a deadline from February 6, 2026, to April 7, 2026, giving companies and patent holders more time to respond. If you’re involved with this medical device, this means a small but important shift in timing for patent extension decisions.

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [C1-2026-02383 on federalregister.gov](https://www.federalregister.gov/documents/2026/03/10/C1-2026-02383/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aurora-ev-icd)
- [C1-2026-02383 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-03-10/pdf/C1-2026-02383.pdf)

## Related
- [Previous: 2026-04705, Sunshine Act Meetings](https://policyrisk.com/federal-register/2026-04705)
- [Next: 2026-04702, University of Texas at Austin; Nuclear Engineering Teaching Laboratory Training…](https://policyrisk.com/federal-register/2026-04702)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/C1-2026-02383 (as of 2026-06-08).
